| 王智,钟太冬,郑惠娟.沙库巴曲缬沙坦联合达格列净治疗T2DM合并心力衰竭患者心功能、糖脂代谢、炎症因子水平的观察.[J].中南医学科学杂志.,2024,(6):1061-1064. |
| 沙库巴曲缬沙坦联合达格列净治疗T2DM合并心力衰竭患者心功能、糖脂代谢、炎症因子水平的观察 |
| Observation of cardiac function, glucose and lipid metabolism, and inflammatory cytokine levels in T2DM patients with heart failure treated with sacubitril valsartan combined with dapagliflozin |
| 投稿时间：2024-05-16 修订日期：2024-10-18 |
| DOI：10.15972/j.cnki.43-1509/r.2024.06.048 |
| 中文关键词: 2型糖尿病 心力衰竭 沙库巴曲缬沙坦 达格列净 |
| 英文关键词:type 2 diabetes mellitus heart failure sacubitril valsartan dapagliflozin |
| 基金项目: |
|
| 摘要点击次数: 78 |
| 全文下载次数: 41 |
| 中文摘要: |
| 目的分析沙库巴曲缬沙坦联合达格列净治疗2型糖尿病(T2DM)合并心力衰竭(CHF)患者心功能、糖脂代谢、炎症因子水平的变化。 方法选取T2DM合并CHF患者85例,分为对照组(达格列净)40例和观察组(沙库巴曲缬沙坦联合达格列净)45例。比较两组心功能、糖脂代谢和炎症因子水平和不良反应情况,分析随访期间主要不良心血管事件(MACE)。 结果与治疗前比较,治疗后两组空腹血糖、餐后2 h血糖、糖化血红蛋白、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、N末端B型脑钠肽前体(NT-proBNP)、可溶性生长刺激表达基因2蛋白(sST2)、血压均降低,高密度脂蛋白胆固醇和左室射血分数(LVEF)升高；且观察组NT-proBNP、sST2、血压低于对照组,LVEF高于对照组(P＜0.05)。与治疗前比较,治疗后两组肿瘤坏死因子-α、白细胞介素-6、超敏C-反应蛋白降低；且观察组低于对照组(P＜0.05)。两组不良反应发生情况比较差异无显著性(P＞0.05)。观察组无MACE平均生存时间高于对照组(P＜0.05)。 结论沙库巴曲缬沙坦联合达格列净可有效改善T2DM合并CHF患者的糖脂代谢、心功能,利于改善其预后。 |
| 英文摘要: |
| AimTo analyze the changes of cardiac function, glucose and lipid metabolism, and inflammatory factors in patients with type 2 diabetes mellitus (T2DM) and heart failure (CHF) treated with sacubitril valsartan combined with dapagliflozin. Methods85 patients with T2DM complicated with CHF were selected and divided into a control group (40 cases, dapagliflozin) and an observation group (45 cases, sacubitril valsartan combined with dapagliflozin). The cardiac function, glucose and lipid metabolism, levels of inflammatory factors, and adverse reactions between two groups were compared, and the major adverse cardiovascular events (MACE) during the follow-up period were analyzed. ResultsCompared with the levels before treatment, both groups showed a decrease in fasting blood glucose, 2-hour postprandial blood glucose, glycated hemoglobin, total cholesterol, triglycerides, low-density lipoprotein cholesterol, N-terminal B-type brain natriuretic peptide (NT proBNP), soluble growth stimulating gene 2 protein (sST2), and blood pressure after treatment, while high-density lipoprotein cholesterol and left ventricular ejection fraction (LVEF) increased; And the observation group had lower NT proBNP, sST2, and blood pressure than the control group, while LVEF was higher than the control group (P＜0.05). Compared with the levels before treatment, the levels of tumor necrosis factor-α, interleukin-6, and high-sensitivity C-reactive protein decreased in both groups after treatment; And the observation group was lower than the control group (P＜0.05). There was no significant difference in the occurrence of adverse reactions between the two groups (P＞0.05). The survival time without MACE in the observation group was higher than that in the control group (P＜0.05). ConclusionThe combination of sacubitril valsartan with dapagliflozin can effectively improve glucose and lipid metabolism, cardiac function, and prognosis in patients with T2DM and CHF. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|